Discussion
Long-term preventive treatment with Takhzyro (lanadelumab-flyo) — approved in the U.S. and the European Union for nearly a decade — substantially reduces the rate of swelling attacks in people with hereditary angioedema (HAE) treated in routine clinical practice. That’s according to the final results of a Phase 4 study…